Evidence map›Paper›PMID 38424235›Full record

ArticleCommunications biology2024

Differential requirements for Smarca5 expression during hematopoietic stem cell commitment.

Tereza Turkova, Juraj Kokavec, Tomas Zikmund, Nikol Dibus, Kristyna Pimkova, Dusan Nemec, Marketa Holeckova, Livia Ruskova, Radislav Sedlacek, Lukas Cermak and 1 more

Open access · goldAbstract read
In one paragraph

Article in Communications biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Chromatin remodeling in tissue stem cell fate determination.Cell regeneration (London, England) · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Tereza Turkova *Hematology Laboratories, BIOCEV; 1st Faculty of Medicine, Charles University, Vestec, Czech Republic.ORCID 0000-0002-5329-1812
Juraj Kokavec *Hematology Laboratories, BIOCEV; 1st Faculty of Medicine, Charles University, Vestec, Czech Republic.ORCID 0000-0003-0267-4570
Tomas ZikmundHematology Laboratories, BIOCEV; 1st Faculty of Medicine, Charles University, Vestec, Czech Republic.ORCID 0000-0003-2452-3749
Nikol DibusLaboratory of Cancer Biology, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic.ORCID 0000-0003-2743-352X
Kristyna PimkovaHematology Laboratories, BIOCEV; 1st Faculty of Medicine, Charles University, Vestec, Czech Republic.ORCID 0000-0002-8033-3651
Dusan NemecHematology Laboratories, BIOCEV; 1st Faculty of Medicine, Charles University, Vestec, Czech Republic.ORCID 0009-0004-3624-9745
Marketa HoleckovaHematology Laboratories, BIOCEV; 1st Faculty of Medicine, Charles University, Vestec, Czech Republic.
Livia RuskovaHematology Laboratories, BIOCEV; 1st Faculty of Medicine, Charles University, Vestec, Czech Republic.
Radislav SedlacekCzech Centre for Phenogenomics, Institute of Molecular Genetics of the Czech Academy of Sciences, Vestec, Czech Republic.ORCID 0000-0002-3352-392X
Lukas CermakLaboratory of Cancer Biology, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic. lukas.cermak@img.cas.cz.ORCID 0000-0002-8777-3692
Tomas StopkaHematology Laboratories, BIOCEV; 1st Faculty of Medicine, Charles University, Vestec, Czech Republic. tstopka@lf1.cuni.cz.ORCID 0000-0001-7236-6894
Charles University · CZCzech Academy of Sciences, Institute of Molecular Genetics · CZCzech Academy of Sciences · CZ

Funding

Grantová Agentura České Republiky (Grant Agency of the Czech Republic) 24-10435S, 24-10353SMinisterstvo Školství, Mládeže a Tělovýchovy (Ministry of Education, Youth and Sports) CZ.02.1.01/0.0/0.0/16_013/0001789, CZ.02.1.01/0.0/0.0/18_046/0015861Ministerstvo Školství, Mládeže a Tělovýchovy (Ministry of Education, Youth and Sports) LX22NPO5102, SVV 260637, UNCE/MED/016, COOPERATIOMinisterstvo Zdravotnictví Ceské Republiky (Ministry of Health of the Czech Republic) NU21-08-00312, NU22-05-00374
6 · The paper itself

Abstract

The formation of hematopoietic cells relies on the chromatin remodeling activities of ISWI ATPase SMARCA5 (SNF2H) and its complexes. The Smarca5 null and conditional alleles have been used to study its functions in embryonic and organ development in mice. These mouse model phenotypes vary from embryonic lethality of constitutive knockout to less severe phenotypes observed in tissue-specific Smarca5 deletions, e.g., in the hematopoietic system. Here we show that, in a gene dosage-dependent manner, the hypomorphic allele of SMARCA5 (S5

Indexed as

HematopoiesisHematopoietic Stem CellsAdenosine TriphosphatasesAnimalsCell DifferentiationMiceAdenosine Triphosphatases

Identifiers

PMID38424235
PMCPMC10904812
OpenAlexW4392286068

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.